| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyBiologicalProcess | cell morphogenesis | HGF L1CAM MBP ADGRB1 GAS7 POU4F2 PRAG1 JMJD1C ATL1 CASK NRXN3 FEZ1 ARL13B LRP1 AUTS2 LEF1 MAP4K4 SLC9A6 MOV10 | 8.43e-06 | 1194 | 105 | 19 | GO:0000902 |
| GeneOntologyBiologicalProcess | cell junction organization | ZNF703 ANK2 CACNA2D2 L1CAM ADGRB1 ZDHHC8 ELFN2 SHISA7 CASK NRXN3 NF1 LRP1 MAP4K4 SLC9A6 PDZRN3 TBX5 | 3.25e-05 | 974 | 105 | 16 | GO:0034330 |
| GeneOntologyBiologicalProcess | negative regulation of cell-substrate adhesion | 3.79e-05 | 74 | 105 | 5 | GO:0010812 | |
| GeneOntologyBiologicalProcess | neuron projection morphogenesis | L1CAM MBP ADGRB1 GAS7 POU4F2 ATL1 CASK NRXN3 FEZ1 LRP1 AUTS2 MAP4K4 SLC9A6 MOV10 | 5.56e-05 | 802 | 105 | 14 | GO:0048812 |
| GeneOntologyBiologicalProcess | negative regulation of cell-matrix adhesion | 6.72e-05 | 43 | 105 | 4 | GO:0001953 | |
| GeneOntologyBiologicalProcess | plasma membrane bounded cell projection morphogenesis | L1CAM MBP ADGRB1 GAS7 POU4F2 ATL1 CASK NRXN3 FEZ1 LRP1 AUTS2 MAP4K4 SLC9A6 MOV10 | 6.96e-05 | 819 | 105 | 14 | GO:0120039 |
| GeneOntologyBiologicalProcess | cell projection morphogenesis | L1CAM MBP ADGRB1 GAS7 POU4F2 ATL1 CASK NRXN3 FEZ1 LRP1 AUTS2 MAP4K4 SLC9A6 MOV10 | 7.62e-05 | 826 | 105 | 14 | GO:0048858 |
| GeneOntologyBiologicalProcess | neuron projection development | HGF L1CAM MBP ADGRB1 GAS7 POU4F2 PRAG1 ATL1 CASK NRXN3 NF1 FEZ1 LRP1 AUTS2 MINAR1 MAP4K4 SLC9A6 MOV10 | 8.03e-05 | 1285 | 105 | 18 | GO:0031175 |
| GeneOntologyBiologicalProcess | regulation of cell projection organization | HGF L1CAM MBP POU4F2 PRAG1 CASK NF1 FEZ1 ADAMTS16 LRP1 AUTS2 MINAR1 MAP4K4 MOV10 | 1.21e-04 | 863 | 105 | 14 | GO:0031344 |
| GeneOntologyBiologicalProcess | negative regulation of cell adhesion | 1.28e-04 | 375 | 105 | 9 | GO:0007162 | |
| GeneOntologyBiologicalProcess | neuron development | HGF L1CAM MBP ADGRB1 GAS7 POU4F2 PRAG1 ATL1 CASK NRXN3 NF1 FEZ1 PITX3 LRP1 AUTS2 MINAR1 MAP4K4 SLC9A6 MOV10 | 1.35e-04 | 1463 | 105 | 19 | GO:0048666 |
| GeneOntologyBiologicalProcess | developmental cell growth | 1.54e-04 | 301 | 105 | 8 | GO:0048588 | |
| GeneOntologyBiologicalProcess | regulation of postsynaptic membrane neurotransmitter receptor levels | 1.94e-04 | 164 | 105 | 6 | GO:0099072 | |
| GeneOntologyBiologicalProcess | chemokine (C-X-C motif) ligand 2 production | 2.40e-04 | 24 | 105 | 3 | GO:0072567 | |
| GeneOntologyBiologicalProcess | regulation of chemokine (C-X-C motif) ligand 2 production | 2.40e-04 | 24 | 105 | 3 | GO:2000341 | |
| GeneOntologyBiologicalProcess | formation of radial glial scaffolds | 2.54e-04 | 5 | 105 | 2 | GO:0021943 | |
| GeneOntologyBiologicalProcess | regulation of neuron projection development | 2.87e-04 | 612 | 105 | 11 | GO:0010975 | |
| GeneOntologyBiologicalProcess | regulation of cell-substrate adhesion | 3.23e-04 | 254 | 105 | 7 | GO:0010810 | |
| GeneOntologyBiologicalProcess | circulatory system development | HGF ANG ANK2 ADGRB1 POU4F2 BCOR ADRA1A NRXN3 NF1 AP2B1 TLR3 ARL13B CTDP1 LRP1 MINAR1 PLG LEF1 TBX5 | 3.36e-04 | 1442 | 105 | 18 | GO:0072359 |
| GeneOntologyBiologicalProcess | regulation of plasma membrane bounded cell projection organization | HGF L1CAM MBP POU4F2 PRAG1 CASK NF1 FEZ1 ADAMTS16 LRP1 AUTS2 MINAR1 MAP4K4 | 3.63e-04 | 846 | 105 | 13 | GO:0120035 |
| Domain | MULTICOPPER_OXIDASE2 | 9.36e-05 | 3 | 105 | 2 | PS00080 | |
| Domain | Cu-oxidase_2 | 1.86e-04 | 4 | 105 | 2 | IPR011706 | |
| Domain | Cu-oxidase_2 | 1.86e-04 | 4 | 105 | 2 | PF07731 | |
| Domain | Cu-oxidase_3 | 3.10e-04 | 5 | 105 | 2 | IPR011707 | |
| Domain | MULTICOPPER_OXIDASE1 | 3.10e-04 | 5 | 105 | 2 | PS00079 | |
| Domain | PAN_AP | 3.10e-04 | 5 | 105 | 2 | SM00473 | |
| Domain | Cu_oxidase_CS | 3.10e-04 | 5 | 105 | 2 | IPR033138 | |
| Domain | Cu-oxidase_3 | 3.10e-04 | 5 | 105 | 2 | PF07732 | |
| Domain | Cu_oxidase_Cu_BS | 4.63e-04 | 6 | 105 | 2 | IPR002355 | |
| Domain | Pan_app | 6.45e-04 | 7 | 105 | 2 | IPR003609 | |
| Domain | PAN | 6.45e-04 | 7 | 105 | 2 | PS50948 | |
| Domain | PAN_1 | 6.45e-04 | 7 | 105 | 2 | PF00024 | |
| Pubmed | An improved smaller biotin ligase for BioID proximity labeling. | 2.74e-06 | 123 | 110 | 6 | 26912792 | |
| Pubmed | TCF20 NEDD1 JMJD1C ATL1 JPH1 ZCCHC14 FAM120A CLPTM1 TMEM131L MAP4K4 PDZRN3 ITPRIPL1 | 3.75e-06 | 733 | 110 | 12 | 34672954 | |
| Pubmed | GAS7 ELFN2 JMJD1C FAM120A POP1 ADAMTS16 LPGAT1 MINAR1 PDZRN3 MOV10 | 3.96e-06 | 493 | 110 | 10 | 15368895 | |
| Pubmed | 9.30e-06 | 152 | 110 | 6 | 38360978 | ||
| Pubmed | 9.66e-06 | 42 | 110 | 4 | 29438518 | ||
| Pubmed | ANK2 autism mutation targeting giant ankyrin-B promotes axon branching and ectopic connectivity. | 9.91e-06 | 2 | 110 | 2 | 31285321 | |
| Pubmed | 9.91e-06 | 2 | 110 | 2 | 22436613 | ||
| Pubmed | 9.91e-06 | 2 | 110 | 2 | 9832558 | ||
| Pubmed | 9.91e-06 | 2 | 110 | 2 | 24671420 | ||
| Pubmed | 9.91e-06 | 2 | 110 | 2 | 14657231 | ||
| Pubmed | Myelin Basic Protein Cleaves Cell Adhesion Molecule L1 and Improves Regeneration After Injury. | 9.91e-06 | 2 | 110 | 2 | 26081148 | |
| Pubmed | Evaluation of ADAMTS12, ADAMTS16, ADAMTS18 and IL-33 serum levels in pre-eclampsia. | 9.91e-06 | 2 | 110 | 2 | 26382559 | |
| Pubmed | 9.91e-06 | 2 | 110 | 2 | 32539223 | ||
| Pubmed | The Functional Proximal Proteome of Oncogenic Ras Includes mTORC2. | 1.38e-05 | 569 | 110 | 10 | 30639242 | |
| Pubmed | 2.14e-05 | 263 | 110 | 7 | 34702444 | ||
| Pubmed | Cooperative polarization of MCAM/CD146 and ERM family proteins in melanoma. | 2.77e-05 | 377 | 110 | 8 | 38117590 | |
| Pubmed | 2.97e-05 | 3 | 110 | 2 | 20006588 | ||
| Pubmed | 2.97e-05 | 3 | 110 | 2 | 11356864 | ||
| Pubmed | 2.97e-05 | 3 | 110 | 2 | 27005929 | ||
| Pubmed | 2.97e-05 | 3 | 110 | 2 | 24988611 | ||
| Pubmed | 2.97e-05 | 3 | 110 | 2 | 28648598 | ||
| Pubmed | 4.02e-05 | 197 | 110 | 6 | 36604605 | ||
| Pubmed | 5.21e-05 | 23 | 110 | 3 | 20159597 | ||
| Pubmed | ENPP6 BICRA HAUS5 ASH1L GAS7 SIK3 BCOR JPH1 SALL2 FAM120A LRP1 TIGD5 PDZRN3 | 5.32e-05 | 1116 | 110 | 13 | 31753913 | |
| Pubmed | 5.40e-05 | 127 | 110 | 5 | 30442766 | ||
| Pubmed | 5.92e-05 | 4 | 110 | 2 | 34380733 | ||
| Pubmed | 5.92e-05 | 4 | 110 | 2 | 11812650 | ||
| Pubmed | 5.92e-05 | 4 | 110 | 2 | 10366625 | ||
| Pubmed | 5.92e-05 | 4 | 110 | 2 | 8786425 | ||
| Pubmed | Giant ankyrin-B mediates transduction of axon guidance and collateral branch pruning factor sema 3A. | 5.92e-05 | 4 | 110 | 2 | 34812142 | |
| Pubmed | 5.92e-05 | 4 | 110 | 2 | 599283 | ||
| Pubmed | 5.92e-05 | 4 | 110 | 2 | 16507336 | ||
| Pubmed | Myelination triggers local loss of axonal CNR/protocadherin alpha family protein expression. | 5.92e-05 | 4 | 110 | 2 | 15579137 | |
| Pubmed | 5.94e-05 | 24 | 110 | 3 | 30348676 | ||
| Pubmed | Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing. | CACNA2D2 BICRA MBP ASH1L CCDC85C CHD2 NEDD1 JMJD1C CCNY NBPF1 CASK FAM120A ZNF33B LRP1 AUTS2 | 7.14e-05 | 1489 | 110 | 15 | 28611215 |
| Pubmed | 8.39e-05 | 225 | 110 | 6 | 12168954 | ||
| Pubmed | 9.52e-05 | 28 | 110 | 3 | 33953184 | ||
| Pubmed | 9.85e-05 | 5 | 110 | 2 | 15647482 | ||
| Pubmed | Subcellular localization of coagulation factor II receptor-like 1 in neurons governs angiogenesis. | 9.85e-05 | 5 | 110 | 2 | 25216639 | |
| Pubmed | 9.85e-05 | 5 | 110 | 2 | 24457100 | ||
| Pubmed | Regulation of the murine Ddelta2 promoter by upstream stimulatory factor 1, Runx1, and c-Myb. | 9.85e-05 | 5 | 110 | 2 | 15778374 | |
| Pubmed | 9.85e-05 | 5 | 110 | 2 | 18628488 | ||
| Pubmed | The STUbL RNF4 regulates protein group SUMOylation by targeting the SUMO conjugation machinery. | TCF20 L1CAM CCDC85C CHD2 DDB2 JMJD1C ATL1 CCNY CLPTM1 LRP1 AUTS2 LPGAT1 PLRG1 | 1.13e-04 | 1203 | 110 | 13 | 29180619 |
| Pubmed | 1.43e-04 | 32 | 110 | 3 | 31338035 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 32634389 | ||
| Pubmed | RA-GEF-1 (Rapgef2) is essential for proper development of the midline commissures. | 1.47e-04 | 6 | 110 | 2 | 21864586 | |
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 19147818 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 31142747 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 30683685 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 28320842 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 21555464 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 21293003 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 18077589 | ||
| Pubmed | 1.47e-04 | 6 | 110 | 2 | 8201022 | ||
| Pubmed | ZNF487 GALNT1 C5orf63 ASH1L OAS1 CHD2 BCOR MEST POP1 ADAMTS18 TMEM131L FUCA2 | 1.68e-04 | 1084 | 110 | 12 | 11544199 | |
| Pubmed | Pax3: a paired domain gene as a regulator in PNS myelination. | 2.06e-04 | 7 | 110 | 2 | 7546735 | |
| Pubmed | 2.06e-04 | 7 | 110 | 2 | 11867212 | ||
| Pubmed | 2.06e-04 | 7 | 110 | 2 | 20053908 | ||
| Pubmed | GPR84 Is Essential for the Taste of Medium Chain Saturated Fatty Acids. | 2.06e-04 | 7 | 110 | 2 | 33941648 | |
| Pubmed | Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. | 2.40e-04 | 38 | 110 | 3 | 18267097 | |
| Pubmed | TCF20 ANK2 SIK3 BCOR SHISA7 CASK NF1 FAM120A AP2B1 LRP1 MAP4K4 | 2.44e-04 | 963 | 110 | 11 | 28671696 | |
| Pubmed | 2.74e-04 | 8 | 110 | 2 | 35011720 | ||
| Pubmed | 2.74e-04 | 8 | 110 | 2 | 27422384 | ||
| Pubmed | Primary cilia are WNT-transducing organelles whose biogenesis is controlled by a WNT-PP1 axis. | 2.74e-04 | 8 | 110 | 2 | 36693320 | |
| Pubmed | 2.74e-04 | 8 | 110 | 2 | 37858465 | ||
| Pubmed | An inducible CRISPR/Cas9 screen identifies DTX2 as a transcriptional regulator of human telomerase. | 2.77e-04 | 180 | 110 | 5 | 35198878 | |
| Pubmed | Synaptic GAP and GEF Complexes Cluster Proteins Essential for GTP Signaling. | 2.80e-04 | 281 | 110 | 6 | 28706196 | |
| Pubmed | Identification and functional characterization of transcriptional activators in human cells. | 2.82e-04 | 398 | 110 | 7 | 35016035 | |
| Pubmed | 2.87e-04 | 529 | 110 | 8 | 14621295 | ||
| Pubmed | 3.52e-04 | 9 | 110 | 2 | 23293286 | ||
| Pubmed | 3.52e-04 | 9 | 110 | 2 | 14530346 | ||
| Pubmed | 3.54e-04 | 105 | 110 | 4 | 9628581 | ||
| Pubmed | 4.37e-04 | 111 | 110 | 4 | 12508121 | ||
| Pubmed | 4.39e-04 | 10 | 110 | 2 | 10707971 | ||
| Pubmed | Essential role for the Prader-Willi syndrome protein necdin in axonal outgrowth. | 4.39e-04 | 10 | 110 | 2 | 15649943 | |
| Pubmed | 4.39e-04 | 10 | 110 | 2 | 17420921 | ||
| Pubmed | Evolutionary history and genome organization of DUF1220 protein domains. | 4.39e-04 | 10 | 110 | 2 | 22973535 | |
| Pubmed | 4.39e-04 | 10 | 110 | 2 | 25487574 | ||
| Pubmed | 4.39e-04 | 10 | 110 | 2 | 15314156 | ||
| Pubmed | 4.39e-04 | 10 | 110 | 2 | 34145365 | ||
| Pubmed | DZIP1 regulates mammalian cardiac valve development through a Cby1-β-catenin mechanism. | 5.35e-04 | 11 | 110 | 2 | 33811421 | |
| Pubmed | 5.35e-04 | 11 | 110 | 2 | 19523119 | ||
| Pubmed | 5.35e-04 | 11 | 110 | 2 | 11435472 | ||
| Pubmed | 5.35e-04 | 11 | 110 | 2 | 19369198 | ||
| Pubmed | 5.35e-04 | 11 | 110 | 2 | 22966238 | ||
| Pubmed | 6.08e-04 | 52 | 110 | 3 | 9455477 | ||
| Pubmed | Genetic analysis of genes involved in amyloid-β degradation and clearance in Alzheimer's disease. | 6.41e-04 | 12 | 110 | 2 | 22027013 | |
| Pubmed | 6.41e-04 | 12 | 110 | 2 | 12490567 | ||
| Pubmed | 6.41e-04 | 12 | 110 | 2 | 37610874 | ||
| Pubmed | Proteomic analysis of in vivo phosphorylated synaptic proteins. | 6.43e-04 | 53 | 110 | 3 | 15572359 | |
| Pubmed | 7.30e-04 | 467 | 110 | 7 | 30194290 | ||
| Pubmed | 7.56e-04 | 13 | 110 | 2 | 30952667 | ||
| Pubmed | 7.56e-04 | 13 | 110 | 2 | 36793543 | ||
| Pubmed | 7.56e-04 | 13 | 110 | 2 | 12668638 | ||
| Pubmed | 7.56e-04 | 13 | 110 | 2 | 26967474 | ||
| Pubmed | 7.56e-04 | 13 | 110 | 2 | 18625210 | ||
| Pubmed | 7.56e-04 | 13 | 110 | 2 | 11456441 | ||
| Pubmed | ISL1 and BRN3B co-regulate the differentiation of murine retinal ganglion cells. | 7.56e-04 | 13 | 110 | 2 | 18434421 | |
| Pubmed | ANK2 ASH1L GAS7 CASK JPH1 FAM120A AP2B1 FEZ1 ARL13B LRP1 REPS2 MAP4K4 | 7.72e-04 | 1285 | 110 | 12 | 35914814 | |
| Pubmed | 7.95e-04 | 57 | 110 | 3 | 34671097 | ||
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.19e-09 | 191 | 110 | 9 | b13229bb7f3713a392271aaf5dbae3edd1b9fe5a | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.25e-09 | 192 | 110 | 9 | f4fc2b0121f879bab2bee99dfb5ff2c3ca1c0e1b | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.25e-09 | 192 | 110 | 9 | dcd924d6eb67d33ee9f5d3e8ab6e1d4283d6b708 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.25e-09 | 192 | 110 | 9 | deeecd26972241846b4cb998edf0c7a87ff0c4df | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.68e-08 | 192 | 110 | 8 | 6f4ef24dab544681304b7f8a9dc073e7edaa4cf5 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.79e-08 | 193 | 110 | 8 | fb28717fadd06c3840636d25409ce80c9254bd34 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.91e-08 | 194 | 110 | 8 | 60622bd2f75bfe4c37f721cb12f03dab33f2f58d | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.54e-08 | 199 | 110 | 8 | 30d3e8c0681ec11f86dd38c5f48d21187a1b4f90 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts-Activated_MatrixFB|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.54e-08 | 199 | 110 | 8 | e1849505b92820a219c5a2c35492bdd55579fb48 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.68e-08 | 200 | 110 | 8 | b79628fd1386aa9a3b0e9fa81def0bc100c3c073 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.68e-08 | 200 | 110 | 8 | 50ca6550998e461ef26dd670351060bd940765a8 | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-Diff_MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 3.68e-08 | 200 | 110 | 8 | 3bdba9612cd7c612b76aa9abecc4a6529aabfc1c | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic-Fibroblasts|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.68e-08 | 200 | 110 | 8 | 44a68bacdb3d5bf563bd35952176995850933a81 | |
| ToppCell | LPS_IL1RA_TNF-Mesenchymal_fibroblastic|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type | 3.68e-08 | 200 | 110 | 8 | dc61016c61729f69649cfb21f6264e685ce83dea | |
| ToppCell | PND07-28-samps-Mesenchymal-Myofibroblast-myofibroblast_-_mature_-_C|PND07-28-samps / Age Group, Lineage, Cell class and subclass | 3.95e-07 | 185 | 110 | 7 | 427176ad9ab8d9511200fb0a132cfd1e835fe35c | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T5|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 4.40e-07 | 188 | 110 | 7 | b070a0667f1ee9b825b267b6c389b7c42fc436f9 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.56e-07 | 189 | 110 | 7 | a153b83314cf52808f685296cff8c95af3f4983d | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.56e-07 | 189 | 110 | 7 | e9d5e858e320c6e9913c1ea6a54967d21eda605f | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.56e-07 | 189 | 110 | 7 | 2a22b9fae70afb3dab8476f9c00e48a4df756410 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 4.73e-07 | 190 | 110 | 7 | d60395739458d7f47a3350ade751fe3819500320 | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.07e-07 | 192 | 110 | 7 | df1545670370fb1010c567cd059c2783eab315f7 | |
| ToppCell | LPS_only-Stromal_mesenchymal|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.07e-07 | 192 | 110 | 7 | 162d8b5858d150ecbbd1c9bf2b19c6c9cd50a158 | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.07e-07 | 192 | 110 | 7 | 3d0cb19f037f604253d7d728689aeaa94251e92b | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.07e-07 | 192 | 110 | 7 | 4e47a02007f562f29ba5910df64d32a0167d0bd1 | |
| ToppCell | wk_20-22-Mesenchymal-Myofibro_&_SMC-Myofibro_2|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 5.25e-07 | 193 | 110 | 7 | 2f203f6f0c2135acb046c9351a633c3b5b254a46 | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.44e-07 | 194 | 110 | 7 | 6e13549f697f7478b34fe71f7dd9d63c5d3db22e | |
| ToppCell | LPS-antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.44e-07 | 194 | 110 | 7 | 89b706af2b25991fc2707eb24f49ba6ff3ae01f7 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.63e-07 | 195 | 110 | 7 | b0d408f8bc1701a87596ed55efcd90749fee33e6 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_mature|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 5.63e-07 | 195 | 110 | 7 | a486a7acea0e91048cc48afa0dbd3926d30bc217 | |
| ToppCell | tumor_Lung-Fibroblasts-COL13A1+_matrix_FBs|tumor_Lung / Location, Cell class and cell subclass | 6.24e-07 | 198 | 110 | 7 | 2d7842f352273b6b823c86eb548b9f4a4cddf0ae | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic|LPS_only / Treatment groups by lineage, cell group, cell type | 6.45e-07 | 199 | 110 | 7 | 211c3a08f2d484ab7a3368006767289088f0d957 | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts|LPS_only / Treatment groups by lineage, cell group, cell type | 6.45e-07 | 199 | 110 | 7 | 1a0add79f4e34078b3475eb11c85a4234bda197c | |
| ToppCell | LPS_anti-TNF-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_anti-TNF / Treatment groups by lineage, cell group, cell type | 6.67e-07 | 200 | 110 | 7 | 9b0916d8d07ac2bf1739f7be5296bf77ffee6094 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic|Control_saline / Treatment groups by lineage, cell group, cell type | 6.67e-07 | 200 | 110 | 7 | 64ae5cf6cb4fc94cf1052abd82648f6b8e6445fe | |
| ToppCell | Parenchymal-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.67e-07 | 200 | 110 | 7 | cf433f9b43d7db07acaf70e060f8f77c974e72f3 | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.67e-07 | 200 | 110 | 7 | cae972324d1dfea6efeaf6013f265c7c6bb48db4 | |
| ToppCell | LPS_only-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_only / Treatment groups by lineage, cell group, cell type | 6.67e-07 | 200 | 110 | 7 | a7ef7022b8efcaedb7319b0b43d8c4e99d788fe2 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 6.67e-07 | 200 | 110 | 7 | 311fab076f2ceb258e3970eb21e39344b894042a | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts|Control_saline / Treatment groups by lineage, cell group, cell type | 6.67e-07 | 200 | 110 | 7 | a1fc74c1b27e104895910bc7cdce7ba33d30df7e | |
| ToppCell | Biopsy_Other_PF-Mesenchymal|Biopsy_Other_PF / Sample group, Lineage and Cell type | 6.67e-07 | 200 | 110 | 7 | d6fcdd48858b53b5a8d18ae14b2dc4d9af41b070 | |
| ToppCell | Control_saline-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|Control_saline / Treatment groups by lineage, cell group, cell type | 6.67e-07 | 200 | 110 | 7 | bd8cf33502adea320e91ca2af14e1911d88ad374 | |
| ToppCell | LPS-IL1RA+antiTNF|World / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.20e-06 | 177 | 110 | 6 | b7fee75de7e96924af488a5baa2334711889ae7c | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.72e-06 | 180 | 110 | 6 | 08ae0f5d95c45feba68ad99788f7af7ff4c979af | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.72e-06 | 180 | 110 | 6 | 9b1de1b4711adbf9a423f4d2d08f3f4c78f1f8f4 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 5.91e-06 | 181 | 110 | 6 | 9e7d0f1afb8d9bc5a209ddb5314df3a25a0274d9 | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.91e-06 | 181 | 110 | 6 | 7286700396676fdc41d9723979b8b408177aceb9 | |
| ToppCell | 10x5'-Liver-Lymphocytic_T_CD4-T_CD4/CD8|Liver / Manually curated celltypes from each tissue | 5.91e-06 | 181 | 110 | 6 | f2315414e714ac86211546a935660c4be6e85f1b | |
| ToppCell | droplet-Limb_Muscle-nan-24m-Macroglial-unknown|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.90e-06 | 186 | 110 | 6 | ea936e66ae4b7b40564711fad60ac0137327995f | |
| ToppCell | Adult-Mesenchymal-matrix_fibroblast_1_cell-D175|Adult / Lineage, Cell type, age group and donor | 7.12e-06 | 187 | 110 | 6 | e15d2967aac248da3517bc2c7d1beaa1d5a0aa7f | |
| ToppCell | 10x5'-GI_small-bowel-Lymphocytic_T_CD4-T_CD4/CD8|GI_small-bowel / Manually curated celltypes from each tissue | 7.34e-06 | 188 | 110 | 6 | ab9b725d6e0cdab8e9ddda6dee09e14730e9a578 | |
| ToppCell | facs-Pancreas-Endocrine-3m-Epithelial-pancreatic_D_cell|Pancreas / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 7.57e-06 | 189 | 110 | 6 | fcc3713e8200d51074f709f3360fb36efb0a639f | |
| ToppCell | LPS-IL1RA+antiTNF-Stromal_mesenchymal-Matrix_Fibroblast-Diff_MatrixFB|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 7.80e-06 | 190 | 110 | 6 | 841cd55861b43578d704418b9bc0af2e8b88323a | |
| ToppCell | 10x5'-lymph-node_spleen-Lymphocytic_T_CD4-T_CD4/CD8|lymph-node_spleen / Manually curated celltypes from each tissue | 8.28e-06 | 192 | 110 | 6 | 47646d7e4990be85072987f92bf18d52f8da752e | |
| ToppCell | LPS_only-Stromal_mesenchymal-Matrix_Fibroblast|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 8.28e-06 | 192 | 110 | 6 | ee085e04d5dcfb657522484ed20b8c1ddeccfe0c | |
| ToppCell | PND07-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway-SCMF-SCMF_prolif|PND07 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 8.53e-06 | 193 | 110 | 6 | f25bdd10ef531b8d8441ea84573078b4b1b0f105 | |
| ToppCell | E18.5-Mesenchymal-Mesenchymal_myocytic-Myofibroblast_airway|E18.5 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.04e-06 | 195 | 110 | 6 | 2414b158dc7bdec43a9671544bfb7ffc5f5168fd | |
| ToppCell | PND01-Mesenchymal-Mesenchymal_myocytic|PND01 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 9.31e-06 | 196 | 110 | 6 | acbb493dbb49a33f20cf11106363f7ed51209706 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-C_(Myofibroblast)|367C / Donor, Lineage, Cell class and subclass (all cells) | 9.86e-06 | 198 | 110 | 6 | a9afedbc0556faf4a46f7bf28f4a9adb3bc859d8 | |
| ToppCell | 367C-Fibroblasts-Fibroblast-C_(Myofibroblast)-|367C / Donor, Lineage, Cell class and subclass (all cells) | 9.86e-06 | 198 | 110 | 6 | 7b5350768f306ec528e271d2ac4470bf668ec6f0 | |
| ToppCell | Biopsy_Control_(H.)-Mesenchymal-Myofibroblasts|Biopsy_Control_(H.) / Sample group, Lineage and Cell type | 1.01e-05 | 199 | 110 | 6 | 7a227c239afdaebcac84644d9b2653a5f1a4be71 | |
| ToppCell | LPS_IL1RA-Mesenchymal_fibroblastic-Fibroblasts-MatrixFB|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 1.01e-05 | 199 | 110 | 6 | a7dd94b172c973a131a6792f8ccd9bfe44d984ac | |
| ToppCell | 10x3'2.3-week_17-19-Mesenchymal_fibro-stroma-arteriolar_fibroblast|week_17-19 / cell types per 3 fetal stages;per 3',per 5' | 1.01e-05 | 199 | 110 | 6 | 95d95e9b7bd3933188998ae94986213eb0f1e5ea | |
| ToppCell | 343B-Fibroblasts-Fibroblast-G|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.01e-05 | 199 | 110 | 6 | f4b6c095cbe7a38b310adc49be4069e4d56e6a66 | |
| ToppCell | 343B-Fibroblasts-Fibroblast-G-|343B / Donor, Lineage, Cell class and subclass (all cells) | 1.01e-05 | 199 | 110 | 6 | 9c6d1c328bfbb6547f4c7bb2a784576a56bd72af | |
| ToppCell | Bronchial-NucSeq-Stromal|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 200 | 110 | 6 | 389cc775c8419d90fb77cd794376d2160a7bf44e | |
| ToppCell | Bronchial-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 200 | 110 | 6 | e8462395fee0a532d1e7ec7f1795f28c42af6541 | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 200 | 110 | 6 | 3dd022e974fec7013ba18f333da63f58fbf2dd7c | |
| ToppCell | Biopsy_IPF-Mesenchymal|Biopsy_IPF / Sample group, Lineage and Cell type | 1.04e-05 | 200 | 110 | 6 | bb605b373caf3f873dc1b87d712704568e0d6040 | |
| ToppCell | Parenchymal-NucSeq-Stromal-Fibroblastic-Fibro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 200 | 110 | 6 | 34f52003988ce6329d8deeee1ab875fa77e01e9d | |
| ToppCell | Tracheal-NucSeq-Stromal-Fibroblastic-Fibro_peribronchial|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 1.04e-05 | 200 | 110 | 6 | 58b38f9a484ee94191091a0659ed62ebed2d4a14 | |
| ToppCell | Control-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.48e-05 | 125 | 110 | 5 | b162a5bfbb8ac5e65e13578fef9de442a9e4fd8b | |
| ToppCell | 5'-GW_trimst-1.5-LargeIntestine-Mesenchymal-fibroblastic-Stromal_3_(KCNN3+)|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.42e-05 | 157 | 110 | 5 | beab0ac47202266b04543c02cfcdda012375e879 | |
| ToppCell | 10x5'-blood-Lymphocytic_T_CD4-T_CD4/CD8|blood / Manually curated celltypes from each tissue | 5.13e-05 | 162 | 110 | 5 | b4535bcb3f469bc139e73f1122f4070013e5a1de | |
| ToppCell | Bronchial-10x5prime-Stromal-Schwann|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.13e-05 | 162 | 110 | 5 | afffecc6c504930554aafc12c5bffa53e3c5b016 | |
| ToppCell | droplet-Heart-nan-18m-Hematologic-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.10e-05 | 168 | 110 | 5 | 2201ae834b53cbdc085f8f02607fa5b5bd911268 | |
| ToppCell | 368C-Endothelial_cells-Endothelial-C_(Capillary_Aerocyte_)-|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.45e-05 | 170 | 110 | 5 | f0b0d2d0402de3ed7322284a599646db43475761 | |
| ToppCell | 368C-Endothelial_cells-Endothelial-C_(Capillary_Aerocyte_)|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells) | 6.45e-05 | 170 | 110 | 5 | 054360a3b05f5e41221c98b122d241b1affad26a | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid-promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-05 | 170 | 110 | 5 | a78d9789c3e7c84a36e1bd380192d7aba4a4d443 | |
| ToppCell | facs-Marrow-T-cells-3m-Myeloid-monocyte_+_promonocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 6.45e-05 | 170 | 110 | 5 | ff68600b945b3a5437b14e5411b3db800d0ccbe5 | |
| ToppCell | ILEUM-inflamed-(9)_Enteric_neurons|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 8.02e-05 | 178 | 110 | 5 | d9142151819afb0dc22bfb32a9c9dba5f553067d | |
| ToppCell | ILEUM-inflamed-(9)_Neuro_cell|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2) | 8.02e-05 | 178 | 110 | 5 | 611504b0a9e6318b18fba83787b03f9245c82252 | |
| ToppCell | human_hepatoblastoma-Tumor_cells-T6|Tumor_cells / Sample and Cell Type and Tumor Cluster (all cells) | 8.23e-05 | 179 | 110 | 5 | 14fc8ccb6b215063d747643f47d780d2b237eb67 | |
| ToppCell | E18.5-samps-Mesenchymal-Myofibroblast|E18.5-samps / Age Group, Lineage, Cell class and subclass | 9.13e-05 | 183 | 110 | 5 | de08f9ea02b7244d5a8788064631d10f06565337 | |
| ToppCell | droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l1-41|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 9.13e-05 | 183 | 110 | 5 | 07ca2786e62eca9feecf5e54a11864a960f7641a | |
| ToppCell | BAL-Mild-cDC_12|Mild / Compartment, Disease Groups and Clusters | 9.61e-05 | 185 | 110 | 5 | e867ed55ab0df018f14bca824da09d36d83e12f9 | |
| ToppCell | E16.5-samps-Mesenchymal-Myofibroblast|E16.5-samps / Age Group, Lineage, Cell class and subclass | 9.86e-05 | 186 | 110 | 5 | e044b3428b7eacfdc72d0f57cdabaa1de04c74cd | |
| ToppCell | droplet-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell-pulmonary_interstitial_myofibroblast|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.01e-04 | 187 | 110 | 5 | 8bd635abdee5d5a12a3f7bf74eab4282e8e40741 | |
| ToppCell | droplet-Limb_Muscle-nan-24m-Macroglial|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.01e-04 | 187 | 110 | 5 | a0bd2b0ec9e73521c245037b1dd51ff8cf24cbf5 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.01e-04 | 187 | 110 | 5 | c104fbfef2d0bef64077ac721edf2379fd59d547 | |
| ToppCell | droplet-Limb_Muscle-nan-24m-Macroglial-Schwann_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.01e-04 | 187 | 110 | 5 | f2af79a20438108c814a73f9e24cd986d537237f | |
| ToppCell | droplet-Lung-18m-Mesenchymal-myofibroblast-myofibroblast_cell|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.01e-04 | 187 | 110 | 5 | 3cb8cd7f7a4306ff74d1f7f9964014008ec1c6a0 | |
| ToppCell | droplet-Trachea-3m-Mesenchymal-myofibroblast-tracheobronchial_smooth_muscle_cell-smooth_muscle_cell_of_trachea_l32-30|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 1.04e-04 | 188 | 110 | 5 | 502045a39ffb1e92bd9499848368e8fa971edb88 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_fibro-stroma|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.06e-04 | 189 | 110 | 5 | eccf3d49354a67c94f1ed7c15a98a48a5e8e2ed0 | |
| ToppCell | 10x5'v1-week_14-16-Mesenchymal_fibro|week_14-16 / cell types per 3 fetal stages;per 3',per 5' | 1.06e-04 | 189 | 110 | 5 | 40764f461b8aa1d3a2c5a30590b7fb9307d47d09 | |
| ToppCell | LPS-IL1RA-Stromal_mesenchymal-Matrix_Fibroblast-Activated_MatrixFB|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.09e-04 | 190 | 110 | 5 | 45df8fee00f8949937863159d7aa042e72748d9b | |
| ToppCell | facs-Lung-nan-3m-Mesenchymal-pulmonary_interstitial_fibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.09e-04 | 190 | 110 | 5 | c7bd087f36321cec61b98657433b4d19d135791f | |
| ToppCell | facs-Lung-nan-3m-Mesenchymal-Myofibroblast|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.09e-04 | 190 | 110 | 5 | 834218fcc59df5e7e52de154272f3d55d81d0dac | |
| ToppCell | Control-Stromal_mesenchymal|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 1.12e-04 | 191 | 110 | 5 | 14057205ddb9b4bbc582d1358d13cf36d979a61b | |
| ToppCell | 3'-Child09-12-SmallIntestine-Neuronal-Glial_mature|Child09-12 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 1.14e-04 | 192 | 110 | 5 | ac507fd7cf3b3e521a15ef03bb4e81eb23807985 | |
| ToppCell | Fetal_29-31_weeks-Mesenchymal-myofibroblast_cell-D150|Fetal_29-31_weeks / Lineage, Cell type, age group and donor | 1.14e-04 | 192 | 110 | 5 | 72881b280a415e65f87a80ca1369cbb0b722a0c4 | |
| Computational | Neighborhood of MAGEA9 | 1.58e-04 | 423 | 63 | 10 | MORF_MAGEA9 | |
| Disease | autism spectrum disorder (implicated_via_orthology) | 1.60e-05 | 152 | 103 | 6 | DOID:0060041 (implicated_via_orthology) | |
| Disease | Acute kidney injury | 8.98e-05 | 25 | 103 | 3 | HP_0001919 | |
| Disease | isthmus cingulate cortex volume measurement | 1.01e-04 | 26 | 103 | 3 | EFO_0010310 | |
| Disease | sciatic neuropathy (is_implicated_in) | 1.20e-04 | 5 | 103 | 2 | DOID:11446 (is_implicated_in) | |
| Disease | fatty acid measurement | 1.49e-04 | 436 | 103 | 8 | EFO_0005110 | |
| Disease | influenza A (H1N1) | 2.50e-04 | 87 | 103 | 4 | EFO_1001488 | |
| Disease | cognitive function measurement, self reported educational attainment | 2.53e-04 | 355 | 103 | 7 | EFO_0004784, EFO_0008354 | |
| Disease | Schizophrenia | CYP2E1 MBP ZDHHC8 ADRA1A NRXN3 FEZ1 TLR3 PITX3 LRP1 AUTS2 PLG | 2.64e-04 | 883 | 103 | 11 | C0036341 |
| Disease | epilepsy (implicated_via_orthology) | 2.74e-04 | 163 | 103 | 5 | DOID:1826 (implicated_via_orthology) | |
| Disease | Neurodevelopmental Disorders | 3.22e-04 | 93 | 103 | 4 | C1535926 | |
| Disease | underweight body mass index status | 4.28e-04 | 9 | 103 | 2 | EFO_0005936 | |
| Disease | cholesteryl esters to total lipids in small LDL percentage | 4.30e-04 | 42 | 103 | 3 | EFO_0022255 | |
| Disease | polyunsaturated fatty acids to total fatty acids percentage | 7.19e-04 | 50 | 103 | 3 | EFO_0022303 | |
| Disease | polyunsaturated fatty acids to monounsaturated fatty acids ratio | 7.62e-04 | 51 | 103 | 3 | EFO_0022302 | |
| Disease | free cholesterol to total lipids in small LDL percentage | 8.52e-04 | 53 | 103 | 3 | EFO_0022286 | |
| Disease | hypertension (is_implicated_in) | 8.70e-04 | 121 | 103 | 4 | DOID:10763 (is_implicated_in) | |
| Disease | Spastic Paraplegia, Hereditary | 1.07e-03 | 14 | 103 | 2 | C0037773 | |
| Disease | triglycerides to total lipids in small LDL percentage | 1.17e-03 | 59 | 103 | 3 | EFO_0022337 | |
| Disease | cholesterol to total lipids in medium HDL percentage | 1.22e-03 | 60 | 103 | 3 | EFO_0022237 | |
| Disease | triglycerides in small VLDL measurement | 1.28e-03 | 61 | 103 | 3 | EFO_0022145 | |
| Disease | triglycerides in small HDL measurement | 1.35e-03 | 62 | 103 | 3 | EFO_0022158 | |
| Disease | phospholipids in large VLDL measurement | 1.35e-03 | 62 | 103 | 3 | EFO_0022169 | |
| Disease | triglycerides to total lipids in very large HDL percentage | 1.35e-03 | 62 | 103 | 3 | EFO_0022339 | |
| Disease | response to antineoplastic agent, response to antimicrotubule agent | 1.40e-03 | 16 | 103 | 2 | EFO_0005260, GO_0097327 | |
| Disease | triglycerides to total lipids in medium VLDL percentage | 1.41e-03 | 63 | 103 | 3 | EFO_0022335 | |
| Disease | cholesterol to total lipids in medium VLDL percentage | 1.41e-03 | 63 | 103 | 3 | EFO_0022239 | |
| Disease | free cholesterol to total lipids in medium LDL percentage | 1.41e-03 | 63 | 103 | 3 | EFO_0022283 | |
| Disease | cholesteryl esters to total lipids in medium VLDL percentage | 1.47e-03 | 64 | 103 | 3 | EFO_0022253 | |
| Disease | testosterone measurement | HGF ZNF703 FMO3 ANK2 CCDC85C SNUPN JMJD1C NF1 AUTS2 MINAR1 MYO15A LEF1 | 1.64e-03 | 1275 | 103 | 12 | EFO_0004908 |
| Disease | triglycerides to phosphoglycerides ratio | 1.76e-03 | 68 | 103 | 3 | EFO_0022327 | |
| Disease | free cholesterol in large VLDL measurement | 1.76e-03 | 68 | 103 | 3 | EFO_0022265 | |
| Disease | triglycerides to total lipids in very small VLDL percentage | 1.83e-03 | 69 | 103 | 3 | EFO_0022341 | |
| Disease | S-6-hydroxywarfarin measurement | 1.87e-03 | 368 | 103 | 6 | EFO_0803326 | |
| Disease | hydrocephalus (implicated_via_orthology) | 1.99e-03 | 19 | 103 | 2 | DOID:10908 (implicated_via_orthology) | |
| Disease | triglycerides to total lipids in small HDL percentage | 2.07e-03 | 72 | 103 | 3 | EFO_0022336 | |
| Disease | methylcobalamin deficiency type cblE | 2.24e-03 | 74 | 103 | 3 | MONDO_0009354 | |
| Disease | free cholesterol to total lipids in large LDL percentage | 2.24e-03 | 74 | 103 | 3 | EFO_0022280 | |
| Disease | transient cerebral ischemia (biomarker_via_orthology) | 2.27e-03 | 157 | 103 | 4 | DOID:224 (biomarker_via_orthology) | |
| Disease | free cholesterol to total lipids in small VLDL percentage | 2.32e-03 | 75 | 103 | 3 | EFO_0022287 | |
| Disease | Anophthalmia-microphthalmia syndrome | 2.43e-03 | 21 | 103 | 2 | cv:C5680330 | |
| Disease | monounsaturated fatty acids; 16:1, 18:1 measurement | 2.60e-03 | 78 | 103 | 3 | EFO_0022187 | |
| Disease | attention deficit hyperactivity disorder, autism spectrum disorder, intelligence | 2.76e-03 | 398 | 103 | 6 | EFO_0003756, EFO_0003888, EFO_0004337 | |
| Disease | malignant astrocytoma (is_marker_for) | 2.91e-03 | 23 | 103 | 2 | DOID:3069 (is_marker_for) | |
| Disease | Cerebral Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0750935 | |
| Disease | Intracranial Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0750936 | |
| Disease | Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0004114 | |
| Disease | Grade I Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C1704230 | |
| Disease | Subependymal Giant Cell Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0205768 | |
| Disease | Mixed oligoastrocytoma | 3.44e-03 | 25 | 103 | 2 | C0547065 | |
| Disease | Pilocytic Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0334583 | |
| Disease | Juvenile Pilocytic Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0280783 | |
| Disease | Diffuse Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0280785 | |
| Disease | Childhood Cerebral Astrocytoma | 3.44e-03 | 25 | 103 | 2 | C0338070 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| SPSHPHMASQSGKRY | 76 | A6NC05 | |
| KGHFRQYPAHVSQPA | 76 | P59817 | |
| LKYSFPGERPSHSLS | 1941 | Q68DN1 | |
| PTNFPIEKTREHYHA | 646 | Q9Y5B0 | |
| GFVEPSSVPYLHLHS | 1126 | Q9NR48 | |
| KVFSSGPDIHYDPHR | 851 | Q6ZU80 | |
| HIGSLASVYHKPPNA | 566 | P63010 | |
| RRSLDNHGYVFKPPH | 791 | Q9NY47 | |
| SYSNIPHEGKHTPLY | 66 | Q5T035 | |
| ANVSKLHLHGSPRYP | 1281 | O14514 | |
| SSKHALGYTLHPPSQ | 351 | P35348 | |
| EPTYHLPSSQGHKRD | 281 | Q8NAV2 | |
| PLGETHHNDFYRKPL | 396 | Q3SXY8 | |
| INHHPPGQIARKYSS | 86 | Q8ND76 | |
| SHGHYPASFSDPETR | 361 | A6NFU0 | |
| PTQPAADTYSEFHKH | 346 | Q6W2J9 | |
| HTINAYHLDPRGPKS | 1171 | Q96F81 | |
| SHVLYKRSTEPHAPG | 201 | Q8TE57 | |
| GYSPSHIPHASQSRE | 226 | Q8TE60 | |
| RYGHSKSPHFREKSP | 136 | Q86U06 | |
| PSQKLGSAYLPSYHH | 851 | Q9UPQ7 | |
| VFRAQPHSTSGLYPH | 706 | Q8HWS3 | |
| FPSFLHYLPGSHRKV | 221 | P05181 | |
| YTISPNPHFHLKLRD | 116 | Q96TA0 | |
| PLITYSDEHFSPGSH | 156 | Q9UJU2 | |
| SPHATAKNGYTPLHI | 621 | Q01484 | |
| HEPFGRIPHNKTYAR | 216 | Q9Y6H3 | |
| TKHPDRFAYPIPHTT | 761 | O14936 | |
| RSKPSFHAPEPKAHY | 546 | O95819 | |
| CSGHHVYPNLPKESF | 146 | P31513 | |
| HFYETGAFPPSKGHK | 316 | Q92604 | |
| HLSSIYAKPQGRLHP | 451 | Q8TC57 | |
| SPYHNFDSVHKAPAS | 196 | Q8NHV4 | |
| EAPFHHSGSRKSLYG | 211 | Q9UKN7 | |
| NEIRSLFPGHPHSAY | 3876 | Q07954 | |
| PPIHHSLERKEGSYS | 1211 | Q15652 | |
| KYSGRHHIPNPSNGE | 531 | Q9HDC5 | |
| HRSIPNGLHDPSSTY | 256 | A6NKD9 | |
| HPQVEFHSYLKGPSQ | 526 | Q8WYN3 | |
| SDLPGHSSYLHERPT | 301 | Q9H3M9 | |
| HPRHYTFASGSPDNI | 381 | O43660 | |
| SLSLVHRYGHSAPPF | 271 | Q8NH61 | |
| RHSLFHSYPPAVSGI | 576 | Q8WXX7 | |
| HEGRSKRNYNPHFPL | 301 | Q6ZU52 | |
| LHKPQSHLYGPGETA | 336 | P32004 | |
| KPQCFYGSSPHHLED | 26 | Q99689 | |
| THFLTQHYDAKPQGR | 31 | P03950 | |
| NSYSNIPHEGKHTPL | 416 | Q9NZB2 | |
| IPHEHSFLPSSYRGK | 156 | P14210 | |
| SLPTPHDDHFGTSYQ | 211 | O94927 | |
| HEYPHFSHRPSTLQA | 371 | P00973 | |
| RGKASFLYSLPHRHP | 276 | Q92466 | |
| SHGPYDSNQPHRKTK | 756 | Q3BBV0 | |
| KGSPYHTGQLHPAVR | 861 | Q92729 | |
| QKLSPTYPAAHHFRS | 61 | O60906 | |
| HYCGPQESKHSDPFR | 891 | Q99575 | |
| PHGASRPILTSYHFK | 436 | Q6GPH6 | |
| ASPQHHLFGVYPSRA | 61 | Q9BXP8 | |
| KPHTSSDLLAQFHYP | 636 | A1KZ92 | |
| TCSDRYNPGHLLPHK | 276 | Q9BTY2 | |
| HVGHVFRKATPYTFP | 341 | Q10472 | |
| KTYFPHFDLHPGSAQ | 41 | P02008 | |
| AATHRHLYHQAFPTP | 531 | Q8WXF7 | |
| SGLPPTFIRFSHHSY | 176 | Q66K79 | |
| QGPSDHYRSFHTDKL | 1756 | O14647 | |
| DYFKPGHPQALRVHS | 501 | Q8IY82 | |
| HHVPLTRPFNFAYTG | 461 | Q6GMR7 | |
| LKNFASRPYSLHPHG | 116 | Q6MZM0 | |
| HPARTAHYGSLPQKS | 196 | P02686 | |
| ASANHGHSPCYPERK | 6 | A6NGU7 | |
| GHHYGPASPQRKDAL | 196 | Q6UWR7 | |
| HQGSVLHPDYKTAFP | 1091 | Q9NZM4 | |
| GAETPKQAFFHLYHP | 266 | Q9Y467 | |
| GFGFSDKPRPHHYSI | 106 | Q5EB52 | |
| DKPRPHHYSIFEQAS | 111 | Q5EB52 | |
| AKQHASFSYPAVHGP | 271 | O75364 | |
| SSISFPAYNHGRHPL | 281 | Q3KNS1 | |
| SKSRLYPQAQHSHYP | 26 | Q9UJV8 | |
| QVFSPHPYPASLKAH | 791 | Q9UPX6 | |
| HGFYSLPKPSRHNTE | 246 | Q9UQC2 | |
| VSTPSHDHSTYPLKG | 206 | Q4G112 | |
| HDHSTYPLKGLDRTP | 211 | Q4G112 | |
| FDHNYLKPLLTHSGP | 541 | Q92581 | |
| GHPVAKILHAYNPSR | 106 | A2VDJ0 | |
| EFLYSHGVPRTLSPH | 486 | Q99593 | |
| SHGPYDSNQPHRKTK | 756 | Q5TAG4 | |
| STSGPHSHDYLPQER | 971 | Q9HCE1 | |
| GSKHHSVPISIYRSP | 61 | Q9HDB5 | |
| HVEPKYSALHSTSPG | 21 | Q12837 | |
| HRSSLPPTVNGYHAS | 121 | O60861 | |
| KNFATRPYTIHPHGV | 116 | Q9BQS7 | |
| HGLPNKVHLSPTAYR | 521 | O75343 | |
| AAHLPQIFSKYPGSH | 166 | Q1XH10 | |
| IHPYGHQPTAAFSKN | 1151 | Q9Y2K2 | |
| RSFHNLSHLPPSYEA | 296 | A6NL88 | |
| HKQTHYSPGSTPLVG | 261 | O95149 | |
| SQSPHAHGYIPSKFP | 211 | P00747 | |
| IHVYFTKSGFHPDPR | 166 | O96005 | |
| PLKYFSHTRKNSPLH | 26 | Q96B21 | |
| RNDAHSLYHKRSPPA | 361 | Q9UM82 | |
| GLSRYHPYGKSHLST | 541 | Q9H7S9 | |
| PHYHGFPVRLFDTSS | 681 | O15455 | |
| SLLFHQIPPSKDSHY | 261 | Q06732 | |
| PHYQRVPLSHGYSKL | 201 | Q8NFH8 | |
| YPIHHGDPSYRTLKE | 2476 | P21359 | |
| CHPPSIKHESYRGNA | 951 | Q9UGU0 | |
| FHGQSFYSTRPPSIH | 76 | Q9UKJ0 | |
| HFSYSLSPGNRHHPV | 861 | Q86YV5 | |
| PHHQLPREGSSSEYS | 406 | Q8WYQ9 | |
| HSPSYAGPKAVAFIH | 681 | Q9ULC8 | |
| PSLRHHNQDKFPASY | 301 | Q53EQ6 | |
| PYELHQRTHTGEKPY | 341 | B1APH4 | |
| FLSPPYKESSHHPLQ | 601 | Q5R3F8 | |
| GKTQATRHHLPPTYS | 66 | A6NMK8 |